Perkin Elmer has expanded its 125I-iodinated radiochemical ligand product line with the addition of 26 labelled compounds.
The expanded product line increases the number of ligands available to scientists involved in disease state research, enabling them to expand their research and drug development efforts.
The 26 compounds include: ACTH (1-39) 2 Tyr, [125I]; ACTH (1-39) 23 Tyr, [125I]; Adrenomedulin (Rat), [125I]; Amyloid 1-40, [125I]; Atrial Natriuretic Factor (Rat), [125I]; Atrial Natriuretic Peptide (Human), [125I]; Bungarotoxin, [125I] High Specific Activity; Calcitonin Tyr 12 (Human), [125I]; Calcitonin Tyr 22 (Salmon), [125I]; Corticotropin Releasing Factor, [125I]; Cortisol, [125I125]; Dendrotoxin, [125I]; Deoxyuridine, [125I]-Iodo-2'; Echistatin, [125I]; Epidermal Growth Factor, [125I]; Fribrinogen (Human), [125125I]; Gastrin Releasing Peptide (Porcine) 15 Tyr, [125I]; Insulin (Human Recombinant), [125I]; Insulin-like Growth Factor 2 (Human Recombinant), [125I]; Iodoaminopotentidine, [125I]; Nerve Growth Factor (Murine), [125I]; Nerve Growth Factor (Human Recombinant), [125I]; Neuropeptide Y (Porcine), [125I]; Oestradiol, [125I]; PDGF, [125I]; and SB258585, [125I].
